Phase 3 Clinical Trials With Primary Completion Dates in December 2025
This is a list of Phase 3 trials with primary completion dates in December 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ASPHF | Ascentage Pharma Group International | 2025-12-01 | Phase 3 | NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CP-CML |
| AVEFF | Avecho Biotechnology Limited | 2025-12-01 | Phase 3 | NCT05840822 | Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia |
| AXSM | Axsome Therapeutics, Inc. | 2025-12-01 | Phase 3 | NCT06413433 | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol |
| BVNRY | Bavarian Nordic A/S | 2025-12-01 | Phase 3 | NCT06844487 | Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC |
| BVNRY | Bavarian Nordic A/S | 2025-12-01 | Phase 3 | NCT06844500 | Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC |
| CLRPF | Clarity Pharmaceuticals Ltd | 2025-12-01 | Phase 3 | NCT06056830 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
| CLVLY | Clinuvel Pharmaceuticals Limited | 2025-12-01 | Phase 3 | NCT06109649 | A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo |
| IMVT | Immunovant, Inc. | 2025-12-01 | Phase 3 | NCT05524571 | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease |
| IMVT | Immunovant, Inc. | 2025-12-01 | Phase 3 | NCT05517421 | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease |
| MLYS | Mineralys Therapeutics, Inc. | 2025-12-01 | Phase 3 | NCT05968430 | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension |
| QNCX | Quince Therapeutics, Inc. | 2025-12-01 | Phase 3 | NCT06193200 | Evaluate the Neurological Effects of EryDex on Subjects With A-T |
| RYTM | Rhythm Pharmaceuticals, Inc. | 2025-12-01 | Phase 3 | NCT05093634 | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway |
| SLS | SELLAS Life Sciences Group, Inc. | 2025-12-01 | Phase 3 | NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 |
| TVTX | Travere Therapeutics, Inc. | 2025-12-01 | Phase 3 | NCT06247085 | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment |
| VNDA | Vanda Pharmaceuticals Inc. | 2025-12-01 | Phase 3 | NCT04652882 | Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) |
| VNDA | Vanda Pharmaceuticals Inc. | 2025-12-01 | Phase 3 | NCT06836557 | Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis |
| XENE | Xenon Pharmaceuticals Inc. | 2025-12-01 | Phase 3 | NCT05614063 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures |
| XFOR | X4 Pharmaceuticals, Inc. | 2025-12-01 | Phase 3 | NCT03995108 | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome |